FEMY
Femasys·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 2
Bearish signal 3
Stock Price Surged Significantly
Consensus Rating "Strong Buy"
RSI Overbought
EPS Below Expectations
Revenue Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About FEMY
Femasys Inc.
A pioneering medical device company specializing in minimally invasive, hormone-based treatments for women's health issues
Healthcare Providers and Services
02/19/2004
06/18/2021
NASDAQ Stock Exchange
69
12-31
Common stock
3950 Johns Creek Court, Suite 100, Suwanee, Georgia 30024
--
Femasys Inc., was incorporated in Delaware on February 19, 2004. The company is a biomedical company dedicated to transforming women's healthcare by developing novel solutions to address areas of significant unmet need. The company is currently a division dedicated to providing reproductive health services to those seeking permanent birth control or infertility solutions.
Company Financials
EPS
FEMY has released its 2025 Q2 earnings. EPS was reported at -0.16, versus the expected -0.18, beating expectations. The chart below visualizes how FEMY has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
FEMY has released its 2025 Q2 earnings report, with revenue of 409.27K, reflecting a YoY change of 84.78%, and net profit of -4.59M, showing a YoY change of 2.11%. The Sankey diagram below clearly presents FEMY's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
